<DOC>
	<DOCNO>NCT02921854</DOCNO>
	<brief_summary>In exploratory study , investigator investigate marker ( molecular immunological ) ICD anti-tumor immunity ( exosomal molecular ) detect serum patient high-dose radiotherapy alone concurrent cisplatin-doublet therapy radiotherapy . For patient : withdraw blood three time treatment analysis .</brief_summary>
	<brief_title>Detection Circulating Biomarkers Immunogenic Cell Death</brief_title>
	<detailed_description>The main aim anticancer therapy exert cytotoxic effect cancer cell . It recently emerge anticancer therapeutic modality capable induce cell death subroutine call immunogenic cell death ( ICD ) mediate specific , sustained anticancer immunity . These observation mark begin intense research immunoadjuvant anticancer immunity induce `` side-effects '' associate anticancer therapy . At present , human , ICD-associated predictive biomarkers identify , hamper development immunological strategy . No publish data human biomarkers ICD available . In vitro , ICD find associate spatiotemporally define emission danger signal surface expose calreticulin ( CRT ) heat shock protein 90 ( HSP90 ) , secrete ATP release TLR4 agonist like HMGB1 HSP70 . Moreover , recently emerge ICD may also associate `` viral response-like chemokine signature ( VCS ) '' capable act 'find ' signal ( granulocytic myeloid cell ) 'keep away ' signal ( immature monocytic myeloid cell ) - detail paradigm investigation . Thus , presence molecular determinant ICD use monitor host immune status predictive biomarker . Examples include : danger signal surrogate positive biomarkers ( HMGB1 , HSP70 autoantibodies CRT/HSP90 ) ; viral-response like chemokine signature direct positive biomarkers ( IFN1A , IFN1B CXCL10 &gt; CCL2 &gt; CXCL1 ) . The presence determinant ICD confirm strategy follow biomarkers ( non-hematological cancer ) : - Cancer cell-associated pro-tumorigenic cytokines/factors IL1A , IL10 , IL6 , TGF-B , VEGFA , VEFGC , IDO enzyme , CXCL12 , IL8 - Immune cell-associated pro-tumorigenic cytokines/chemokines/factors IL10 , IDO enzyme , TGF-B , IL4 , IL5 , IL13 , TNF , M-CSF , GM-CSF , IL26 , CXCl5 , CCL7 - danger signal surrogate positive biomarkers HMGB1 , HSP70 autoantibodies CRT/HSP90 - Cancer cell-associated viral response-like chemokine signature IFN-a , IFN-b , CXCL9 , CXCL10 , CXCL1 CCL2 - Immune cell-associated anti-tumorigenic cytokine chemokines positive biomarkers IL1B , IL12p70 , IL15 , IFNG , IL22 , IL23 , IL17A , IL2 , CCL4 , CCL5 , CXCL13 , CCL8 , CCL19 , CXCL11 , CCL12 , CCL17 , CCL23 , CCL22 , CCL13 , CCL24 , CCL1 , CCL26 , CXCL2 , CXCL16 Moreover , investigator also investigate serum-associated exosomes possible biomarkers efficient antitumor response . Compared certain soluble biomarkers ( accessible thus susceptible extracellular protease ) , exosomal biomarkers exhibit longer half-life soluble equivalent , due `` protection '' provide encompass lipid membrane . Therefore , investigator also interested exploit exosomes source antitumor response information novel biomarkers therapeutic success ( mention others investigation ) . Radiotherapy establish various robust line vitro vivo evaluation capable induce ICD anticancer immune response . As exploratory analysis , integrate lipidomics workflow . This already do multiple disease setting NSCLC already proven change lipid content quantifiable manner . The aim pilot study investigate hypothesis certain biomarkers ICD identify vitro ex vivo detectable patient serum follow radiotherapy and/or chemotherapy . Radiotherapy alone concurrent cisplatin-doublet radiotherapy investigate . The investigator conduct pilot study gather initial data build upon future clinical trial , vivo data available topic . Results publish used future grant application .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Male female , age 18 year . Diagnosed nonsmall cell lung cancer Scheduled receive one follow two therapeutic strategy : Concurrent cisplatindoublet chemotherapy radiotherapy ( minimal dose 60 Gy fractionate nonablative dos ) patient stage III NSCLC SBRT stage I NSCLC : 54Gy 3 fraction , 48 Gy 4 fraction 60 Gy 8 5 fraction Is able willing comply trial requirement . 1 . Chronic use corticosteroid , except use antiemetic chemotherapy inhaler 2 . NSAIDs take 5 day radiotherapy radiation ( low dose Aspirin maximum 160 mg/day , allow ) 3 . Active autoimmune diseases 4 . Immunosuppressive medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>